Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors

21 Oct 2020

Abstract excerpt

Abstract MYC is a highly validated oncogenic transcription factor and cancer target. However, the disordered nature of this protein has made it a challenging target, with no clinical stage, direct small-molecule MYC inhibitors available. Recent work leveraging a large in silico chemical library and a rapid in vivo screen has expanded the chemotypes of direct small-molecule inhibitors (MYCi). Novel MYCi represent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33087323
DOI: 10.1158/0008-5472.can-20-2959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Turning Up the Heat on MYC: Progress in Small-Molecule InhibitorsPMID 33087323Read ↗

MYC modulators in cancer: a patent reviewSemantic proximity Read ↗

MYC as a Target for Cancer Treatment: from Undruggable to Druggable?Semantic proximity Read ↗

Alternative approaches to target Myc for cancer treatmentSemantic proximity Read ↗

MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent MannerSemantic proximity Read ↗

A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferationSemantic proximity Read ↗

Taking on challenging targets: making MYC druggable.Semantic proximity Read ↗

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent CancersSemantic proximity Read ↗

Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-MycSemantic proximity Read ↗

Strategies to target the cancer driver MYC in tumor cellsSemantic proximity Read ↗

Enhancing c-MYC degradation via 20S proteasome activation induces <i>in vivo</i> anti-tumor efficacySemantic proximity Read ↗

Cell-based methods for the identification of MYC-inhibitory small molecules.Semantic proximity Read ↗

A novel inhibitor L755507 efficiently blocks c-Myc–MAX heterodimerization and induces apoptosis in cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.